CheckMate 140:纳武利尤单抗治疗复发/难治性滤泡性淋巴瘤的2期研究
该2期研究纳入92例既往至少2线治疗(每线含CD20抗体或烷化剂)的复发/难治性滤泡性淋巴瘤患者,接受纳武利尤单抗3 mg/kg每2周治疗。中位随访至少12个月后客观缓解率仅4%(4/92),中位无进展生存期2.2个月,疗效有限,安全性与此前报道一致。
要点
- 复发/难治性滤泡性淋巴瘤中纳武利尤单抗单药客观缓解率仅4%。
- 中位无进展生存期2.2个月,中位缓解持续时间11个月。
- 应答者肿瘤微环境中CD3+ T细胞比例显著高于非应答者。
核心结论
- 纳武利尤单抗单药在复发/难治性滤泡性淋巴瘤患者中活性非常有限。
- 需更好理解该病免疫生物学以开发有效的检查点抑制剂策略。
研究设计与样本
- 2期单臂试验,共92例复发/难治性滤泡性淋巴瘤患者接受治疗。
- 入组要求既往至少2线治疗,每线含CD20抗体或烷化剂。
- 治疗方案为纳武利尤单抗3 mg/kg每2周静脉给药。
- 主要终点为独立影像评审委员会评估的客观缓解率。
- 生物标志物分析包括治疗前肿瘤样本的基因表达谱与多重免疫荧光。
主要发现
- 至少随访12个月后,客观缓解率为4%(4/92)。
- 中位无进展生存期为2.2个月(95%CI 1.9-3.6个月)。
- 中位缓解持续时间为11个月(95%CI 8-14个月)。
- 应答者肿瘤微环境中CD3+ T细胞比例显著高于非应答者。
- PD-1或PD-L1表达在应答者与非应答者间无显著差异。
关键数值与推荐
- 客观缓解率4%(4/92),为主要终点。
- 中位无进展生存期2.2个月(95%CI 1.9-3.6个月)。
- 中位缓解持续时间11个月(95%CI 8-14个月)。
- 巨噬细胞基因高表达与PFS缩短相关:HR 3.28(95%CI 1.76-6.11),P=.001。
临床怎么用
- 不建议在复发/难治性滤泡性淋巴瘤中常规使用纳武利尤单抗单药。
- 肿瘤微环境CD3+ T细胞及巨噬细胞基因表达或可辅助筛选潜在获益人群。
局限性
- 为单臂2期研究,无对照臂。
- 客观缓解率极低,疗效结论受限。
- 生物标志物分析为探索性,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nivolumab, an anti-programmed death-1 (PD-1) monoclonal antibody, showed promising activity in relapsed or refractory (R/R) follicular lymphoma (FL) in a phase 1 study. We conducted a phase 2 trial to further evaluate its efficacy and safety in patients with R/R FL and to explore biomarkers of response. Patients with R/R FL and at least 2 prior lines of therapy, each containing a CD20 antibody or an alkylating agent, were treated with nivolumab 3 mg/kg every 2 weeks. The primary end point was objective response rate (ORR) assessed by an independent radiologic review committee. Biomarker analyses included gene expression profiling and multiplex immunofluorescence studies of pretreatment tumor samples. A total of 92 patients were treated. After a minimum follow-up of 12 months, ORR was 4% (4 of 92 patients). Median progression-free survival (PFS) was 2.2 months (95% confidence interval [CI], 1.9-3.6 months). Median duration of response was 11 months (95% CI, 8-14 months). Exploratory analyses suggested that responders had significantly higher proportion of CD3+ T cells in the tumor microenvironment than nonresponders, but no significant differences in PD-1 or programmed death-ligand 1 expression were observed. High expression of a set of tumor-associated macrophage genes was associated with reduced PFS (hazard ratio, 3.28; 95% CI, 1.76-6.11; P = .001). The safety profile was consistent with previous reports of nivolumab. In conclusion, nivolumab monotherapy was associated with very limited activity in patients with R/R FL. Better understanding of the immune biology of this disease may facilitate the development of effective checkpoint-based strategies. This trial was registered at www.clinicaltrials.gov as #NCT02038946.
引用
- Armand P, Janssens A, Gritti G, et al. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. 2021. PMID: 32870269. doi:10.1182/blood.2019004753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。